Modelling the costs and benefits of an mRNA compared to a DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada
Cases of cervical cancer in Canada have decreased recently as a result of cytology-based screening programs. However, cervical cancer remains a relatively common and preventable cause of cancer in women. As cervical cancer is primarily caused by persistent genital infection with high-risk (HR) human papillomaviruses, Ontario Health has been evaluating implementing HPV-based testing in cervical Read More >
Research in Dravet syndrome and cervical cancer screening presented at international conferences
Aquarius has recently presented posters at international conferences (ISPOR, a conference for the leading professional society for health economics and outcomes research and EUROGIN, an international multidisciplinary HPV conference), exploring the impact of improving healthcare for two very different conditions: Dravet syndrome (rare debilitating epilepsy) and cervical cancer. Read More >
An exciting start to 2021
The challenges and opportunities of growing a team during these strange times 2020 was a year like no other, including for the team at Aquarius. We learned how to work from home and adapt to seeing our colleagues and clients on our screen. Members of the team have had to juggle the roles of worker Read More >
Aquarius gives back in 2020
Working with us gives health, wellbeing and safety to those who need it most Aquarius Population Health is passionate about improving health and wellbeing at home and abroad. We are extremely fortunate that our work makes a real difference to the health of the wider population, and that our team is able to grow and Read More >
Is it cost effective to screen women for syphilis twice during pregnancy?
The UK National Screening Committee (UK NSC) asked Aquarius to assess the costs and benefits of two different approaches to antenatal screening for syphilis. We compared the current strategy – screening in the first trimester only – with an alternative strategy – screening in the first trimester and a repeat screen later in pregnancy. The Read More >
Could we optimise testing for gonorrhoea to avoid the use of last-line antibiotics?
Ceftriaxone is the first-line treatment for gonorrhoea but there are few alternative treatments available should ceftriaxone resistance become widespread. Aquarius created a model to explore how point-of-care testing could be used to diagnose gonorrhoea and at the same time test for antibiotic susceptibility, which could allow the use of previously abandoned antibiotics for many patients, Read More >
How can economic models inform decision-making about screening programmes?
Dr Elisabeth Adams, Managing Director and Founder of Aquarius Population Health, spoke at a continuing medical education webinar for health professionals hosted on September 23,2020 by the Consortium for Infectious Disease Control (CIDC). With increasing demands on time and resources, decision-makers in healthcare need information about how to create a safe, effective and cost-effective Read More >
Aquarius part of collaborative NIHR grant to evaluate Odin Vision’s artificial intelligence technology to fight bowel cancer
In the UK, 42,000 new diagnoses and 16,000 deaths occur from bowel cancer each year. Bowel cancer is the second most common cause of cancer death in the UK, comprising over 10% of all deaths due to cancer. (1) A recent study found that almost one third of bowel cancer patients experience an avoidable delay Read More >
Sexual Health
Improving clinical decision making and patient management
How much would community-based screening for chlamydia and gonorrhoea cost?
We collaborated with St George’s, University of London, on a NIHR-funded study ‘Test n Treat’ (TnT). This study assessed the cost of providing same-day chlamydia and gonorrhoea testing and treatment service at higher education colleges. The paper presenting this work was published in BMC Health Services Research and is now available online. Read More >